Search
  • Search

    REQUEST FOR INFORMATION: MLPA-Based CNV Testing for BRCA1/BRCA2

    HUS-yhtymä

    REQUEST FOR INFORMATION: MLPA-Based CNV Testing for BRCA1/BRCA2

    1. Planning notice published

      Mar 26, 12:22 PMMarch 26, 2026 12:22 PM

    2. Planned competition start

      May 1, 12:00 AMMay 1, 2026 12:00 AM

    Brief

    Finland: Tenders/HUS-yhtymä/REQUEST FOR INFORMATION: MLPA-Based CNV Testing for BRCA1/BRCA2

    Published deadline passed

    The published deadline has passed. For multi-stage competitions a later tender deadline may still apply — check the notice or portal for the current phase.

    Brief

    Laboratorie- og analyseutstyr

    HUS Group, the joint authority for Helsinki and Uusimaa, is planning the procurement of MLPA-Based CNV Testing for BRCA1/BRCA2 to analyze copy number variations in BRCA1 and BRCA2 genes. Suppliers are encouraged to submit responses via email to kilpailutus.diagnostiikka@hus.fi, including a contact person and email address for potential bilateral market dialogue, and may attach brochures related to proposed products and services.

    About the bid

      With this request for information (RFI), HUS Group launches a market consultation to prepare a forthcoming procurement. The aim of this RFI is to find suppliers operating in this field of business, get information of the solutions available in the market, and inform our plans and requirements for the forthcoming procurement. DESCRIPTION OF THE SUBJECT OF THE REQUEST FOR INFORMATION HUSLAB Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is a SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic and follow-up genetic testing services to all patients at Helsinki University Hospital area. The services include analysis of both constitutional samples and malignancies. This Request for Information is released for preliminary evaluation and market research for copy number variations (CNVs) in BRCA1 and BRCA2 genes by MLPA (Multiplex Ligation-dependent Probe Amplification). INSTRUCTIONS FOR ANSWERING Responses to this request for information must be submitted in English or Finnish by email to kilpailutus.diagnostiikka@hus.fi no later than 14 April 2026. The subject line of the email must include: HUS 589-2025 MLPA-Based CNV Testing for BRCA1/BRCA2. The response must include all the information requested below in sections 1–8. The respondent is also requested to provide a contact person and an email address for potential bilateral market dialogue and additional information requests from the contracting authority. Respondents may also attach any available brochures related to the proposed products and services. Requirements to be addressed in the RFI Response: 1. Technology and Performance 1.1 Performance across different sample types (whole blood, FFPE), including examples of analytical accuracy, sensitivity, and limits of detection. 1.2 How are detection limits determined for different sample matrices? 2. Workflow and Capacity 2.1 Turnaround time for the laboratory work. 2.2 How many samples can be processed simultaneously? 3. Validation and References 3.1 Available validation data. 3.2 User references. 4. Reagent Composition 4.1 Complete list of required components. 4.2 Available kit sizes. 4.3 Availability of ready-to-use controls for assays? 4.4 Availability and supply reliability. 4.5 CE-IVD marking. 5. Software and Data Management 5.1 Required software. 5.2 Required IT systems for instrument operation and data analysis. Are these included in the total price? 5.3 How is the analysis performed? 5.4 Supported file formats. 6. Support 6.1 Availability of (local) technical support. 7. Cost Estimate 7.1 Estimated costs for kits/consumables, and the maintenance. 8. Product Descriptions and Delivery Time 8.1 Descriptions of the proposed products. 8.2 An estimation of the delivery time of the proposed products.

      Contact name
      Diagnostiikka
      Contact phone
      +358 94711
      Contact email
      kilpailutus.diagnostiikka@hus.fi
      Address
      Uutistie 5, 01770 Vantaa

    Custom Assessment Criteria

    Start a free trial to ask your own questions about the tender and get AI-generated answers.

    Award Criteria

      Found no award criteria in the contract notice.

    Qualification requirements

      Found no qualification requirements in the contract notice.

    Previous Contract Winners

    Start a free trial to see who has won similar tenders for this buyer.

    See the full notice

    Contracting authority
    HUS-yhtymä
    Title
    REQUEST FOR INFORMATION: MLPA-Based CNV Testing for BRCA1/BRCA2
    Type
    Planning
    Main code
    33696500Laboratory reagents
    Supplemental codes
    33000000Medical equipments, pharmaceuticals and personal care products
    Location
    Helsinki-Uusimaa

    Active similar competitions

    • HUS-yhtymä

      Laboratorie- og analyseutstyr

      MLPA-Based CNV Testing for BRCA1/BRCA2

      HUS Group, the joint authority for Helsinki and Uusimaa, needs an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licenses, and other components required for routine use and generation of reportable patient results. The contract period is 2 years, after which it continues indefinitely until terminated. The estimated annual consumption is approximately 1600 reportable patient samples, to be delivered to the HUSLAB Laboratory of Genetics in Helsinki-Uusimaa, Finland. The award criterion is the lowest total comparison price.

      CompetitionOct 7, 2026
      Nov 9, 2026(11 days)

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      REQUEST FOR INFORMATION: SPRI Beads

      HUS-yhtymä is planning the procurement of DNA size selection reagents based on paramagnetic beads, utilizing SPRI technology for selective binding and purification of DNA fragments, to be used in next-generation sequencing (NGS) library preparation. Suppliers can provide feedback and input by submitting a response via email to kilpailutus.diagnostiikka@hus.fi, addressing all requirements, providing requested information and documentation, and identifying any concerns or proposed amendments to the draft agreement.

      PlanningAug 18, 2026
      Nov 1, 2026(3 days)

    • HUS-yhtymä

      Farmasøytisk engroshandel

      Request For Information – Supply of Boronophenylalanine for pharmaceutical preparation of compound for BNCT treatment

      HUS Group, the joint authority for Helsinki and Uusimaa, is planning the procurement of L-4-boronophenylalanine (BPA) for the pharmaceutical preparation of a compound used in BNCT treatment. Suppliers are asked to provide information on order size, delivery time, shelf-life, quality assurance, and regulatory requirements, and can send questions to HUS Pharmacy to arrange an active discussion.

      PlanningSep 2, 2026

    • HUS-yhtymä

      Laboratorie-kits og reagenser

      Automaattinen nukleiinihappojen eristyslaite

      HUS-yhtymä suunnittelee automaattisen nukleiinihappojen eristyslaitteen hankintaa HUS Diagnostiikkakeskuksen Kliinisen mikrobiologian nukleiinihappoanalytiikkaan, sisältäen laitteen, varalaitteen tai kaksi erillistä eristysmoduulia sekä tarvittavat reagenssit ja tarvikkeet. Hankittavalla laitteella on tarkoitus eristää bakteeri-DNA:ta useista eri näytemateriaaleista, ja eristetyn tuotteen tulee olla validoitu bakteerien 16S-geenin PCR-monistamiseen Sanger-sekvensoinnilla. Toimittajia pyydetään tutustumaan liitteenä oleviin kysymyksiin ja toimittamaan vastaukset sähköpostitse osoitteeseen kilpailutus.diagnostiikka@hus.fi. bioMérieux Suomi OY:llä on todennäköisesti sopimus tällä hetkellä.

      PlanningSep 16, 2026
      Jan 16, 2027(79 days)

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      Request for information: Radioactive seeds (I-125) and plaques (Ru-106) used in eye brachytherapy

      HUS Group is planning the procurement of radioactive products, specifically Iodine-125 (I-125) brachytherapy seeds and Ruthenium-106 (Ru-106) eye plaques/applicators, along with related accessories for the treatment of epibulbar and intraocular tumors. Suppliers are asked to provide information on their product portfolios, typical delivery times, and available options for accessories, quality assurance, and treatment planning systems by submitting their responses via email to kilpailutus.tiimi@hus.fi. Eckert & Ziegler BEBIG GmbH likely has the contract today.

      PlanningOct 5, 2026
      Jan 25, 2027(88 days)